ARWR: Arrowhead Pharmaceuticals Inc

ARWR News

• Investing 13:40 Sarepta stock jumps as FDA may lift ELEVIDYS pause after safety review
• Investing 11:38 Sarepta Therapeutics stock price target raised to $5 from $0 at H.C. Wainwright
• Benzinga 09:41 Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? - Arrowhead Pharma (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT)
• Investing 08:54 Bernstein initiates Sarepta Therapeutics stock with Market Perform rating
• Investing 08:08 Sarepta Therapeutics stock rating upgraded by JPMorgan on FDA decision
• Benzinga 12:48 FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys - Sarepta Therapeutics (NASDAQ:SRPT)
• Investing 11:55 H.C. Wainwright reiterates Sell rating on Sarepta Therapeutics stock with $0 target
• Investing 07:38 Barclays downgrades Sarepta stock to Underweight on Elevidys concerns
• Benzinga 15:09 Sarepta Gets Thumbs Down From Regulators Regarding Gene Therapy - Sarepta Therapeutics (NASDAQ:SRPT)
• Investor's Business Daily 14:04 Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
• Investing 18:01 Eli Lilly, GE Vernova Surge Among Wednesday’s Market Cap Stock Movers
• Benzinga 15:00 GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Arrowhead Pharma (NASDAQ:ARWR), Abivax (NASDAQ:ABVX)
• Seeking Alpha 17:30 How Negative Developments At Sarepta Impact Arrowhead Pharmaceuticals (NASDAQ:ARWR)
• Investor's Business Daily 12:58 Sarepta Makes A 'Painful' Decision. Will It Help Rebuild Investors' Confidence?
• Benzinga 12:56 Sarepta Pauses Elevidys Shipments Amid FDA Safety Review - Sarepta Therapeutics (NASDAQ:SRPT)
• Investing 18:01 Google, Linde lead market cap stock movers on Monday
• Investing 18:01 Netflix, Abbott Labs Lead Friday’s Market Cap Stock Movers
• Zacks 14:58 SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
• Investing 15:17 CRISPR Therapeutics stock maintains outperform rating at William Blair
• Investing 11:44 Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
• Investing 21:20 Factbox-Fat, not muscle: Drugmakers in race for next weight-loss breakthrough
• Reuters 14:41 Fat, not muscle: drugmakers in race for next weight-loss breakthrough
• Investing 19:07 Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans
• Investing 15:31 Arrowhead at Jefferies Conference: Strategic Pipeline Insights